Brian Bettencourt, Ph.D.


I’m humbled that I get to help turn strings of RNA letters in my computer – A U C and G – into medicines that are helping patients every day. How cool is that?!

Brian Bettencourt

Brian joined TRV as an entrepreneur-in-residence in 2022, focused on scientific strategy and execution of RNA-based drug development at Third Rock portfolio companies. He loves inquiry at the intersection of computational and “wet” biology, and especially appreciates the speed with which RNA drugs test clinical hypotheses. Brian has worked in a variety of diverse roles in biotech, and seeks to create companies that foster and reward similar career flexibility.

Prior to Third Rock, Brian was instrumental in the launch of three biotech companies, including Triplet Therapeutics, where he was Head of Research. He also held leadership roles in bioinformatics and biometrics at Translate Bio and Alnylam Therapeutics. It was at Alnylam that Brian got his first direct experience with an oligonucleotide completing the journey from a sequence of letters on a computer all the way to a life-saving medicine. Before joining the biotech industry, Brian was a biology professor with a research focus on Drosophila population genetics and neurodegeneration models.

Outside the office and the lab, Brian’s main loves are gardening, playing music, and herding his rambunctious children (which is impossible without his wife’s patience and help!). Brian also spends a lot of his free time working on scientific projects for rare disease foundations, and he can’t imagine a more rewarding pastime.

Year Joined
  • 2022
  • BS Biology, UMass Amherst
  • PhD Organismal Biology and Anatomy, University of Chicago
  • East Coast